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We thank Krause and colleagues [[1]] and Burger [[2]] for the extremely supportive comments to our 
proposal for a PhD curriculum in drug development [[3]]. Their comments clearly highlight the high 
need for fit for purpose training in drug development at PhD level and support the multi-faceted 
approach taken in our proposal. Moreover, the increasing demand for these highly qualified 
researchers in the light of the evolving landscape of drug development has been well articulated by 
Burger [2].  
How to best train young researchers in evolving statistical methodology such as adaptive designs 
[[4],[5]], dose finding [6,7,8] and analysis methods [9,10,11]? Traditionally, universities play a central 
role in the conception and implementation of students training. Academic institutions are the most 
experienced to propose and run well-designed teaching programmes. However, as pointed out by 
both comments – and how our proposal for a new PhD programme on quantitative methods for 
drug development is conceptualized – strong involvement of other stakeholders in the construction 
and execution of such a new PhD programme is key for a successful and sustainable implementation. 
Public-private partnership is essential to tailor to the needs of all stakeholders, to enlarge the 
possible experiences and to facilitate application of the newly developed approaches. For this, the 
pharmaceutical industry and regulatory agencies will play a key role. The growing demand in 
industry has been highlighted in [2] while the latter also has an accumulated demand for highly-
trained statisticians [12,13,14]. The European Medicines Agency (EMA) established its Biostatistics 
working party only 10 years ago [15] and its creation has resulted in substantial additional 
recruitment of statisticians within regulatory bodies. Thus there is a growing demand for graduates 
of such a quantitative programme in both industry and within regulatory agencies. This high demand 
was also experienced in the H2020 funded project IDEAS (“Improving Design, Evaluation and Analysis 
of early drug development Studies”): all former IDEAS students found new posts immediately after 
completion of their studies – most of them in the pharmaceutical industry. The transfer of 
knowledge between academia, regulatory agencies and industry will help to raise the acceptance 
and willingness to implement novel designs and methods faster.  
We note with great interest the parallels drawn to the development of Pharmacometrics and 
certainly welcome close collaboration, as we believe Pharmacometrics is an indispensable part of 
drug development. Consequently, a solid understanding of Pharmacometrics is crucial for 
quantitative drug developers making this an essential aspect of any training programme in this field. 
In the IDEAS programme this is reflected in several of the research projects working on topics within 
Pharmacometics [16,17]. In our proposal this is recognised in several formal training courses that 
capture (some) of the areas of Pharmacometics. The dedicated course on Pharmacological modelling 
has been identified explicitly in the comments, but of course other aspects of Pharmacometrics are 
captured elsewhere as well. Modelling techniques are ubiquitous throughout the course programme 
(e.g. dose-finding, Statistical methods for research and preclinical development) and simulation 
would be a core element of the advanced computational skills training. We do, however, appreciate 
that further expansion of these areas and links between the disciplines are desirable. For that 
purpose, it may be useful to develop additional post-graduate level certifications in 
Pharmacometrics and Quantitative drug development to further supplement the proposed 
programme and existing Pharmacometrics programmes, respectively.   
Last but not least, the name of such a PhD programme is an important factor. It will decide how 
many and which type of students will be attracted to enrol in such a program. We especially enjoyed 
the recollection by Krause et al. [1] on which labels have been used for the field of Pharmacometrics 
over the last decades. We recognize that “curriculum on quantitative methods for drug 
development” might leave some room for improvement and are open for suggestions and ideas for 
further collaborations. 
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